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Acute kidney injury (AKI) is a known complication af-ter transcatheter aortic valve implantation (TAVI),1-7 with a reported incidence of 8.3%-57.0%.1,5 Severe 
AKI is one of the strongest predictors of postprocedural 30-
day mortality and is associated with worse mid- and long-
term outcomes.3,4,8-10 Discrepancies still exist regarding the 
association between AKI and mortality.11,12 Helgason et al12 
found AKI to be an independent predictor of procedural 
mortality (odds ratio [OR], 5.89; 95% confidence interval 
[CI], 1.99-18.91), but not of long-term survival (hazard ratio 
[HR], 1.44; 95% CI, 0.86-2.42)..
On the other hand, chronic kidney disease (CKD) was 
associated with worse outcomes.13-16 Uncertainty exists 
with regard to predictors of AKI; different baseline char-
acteristics and procedural circumstances were suggested as 
predictors, including commonly used surgical risk scores, 
such as the EuroScore II and Society of Thoracic Surgeons 
(STS) score. However, the currently available scores lack 
predictive accuracy.17-19 
In the current study, we sought to assess significant pre-
dictors of AKI in patients undergoing TAVI, solely by iden-
tifying the strongest baseline risk factors. 
Methods
Patients. All patients included in the current study were 
enrolled in the SWISS TAVI registry, which mandated ob-
taining a voluntary consent prior to any intervention.
The Zurich study population included 335 consecutive 
patients who underwent TAVI at the University Hospital 
of Zurich from 2012 to 2015 and had completed 1-year 
follow-up. A group of 191 consecutive TAVI patients from 
Cardiocentro Ticino were also included in the current anal-
ysis, bringing the entire study population to 526 patients 
who were evaluated for the development of postprocedural 
AKI within 7 days post TAVI. All patients were assessed for 
perioperative and long-term risk for TAVI by means of Eu-
roScore II; STS score; baseline age, creatinine and ejection 
fraction (ACEF) score; echocardiography; clinical presenta-
tion; and baseline characteristics, such as laboratory parame-
ters and comorbidities.
Definitions. Baseline CKD stages were defined according 
to Kidney Disease: Improving Global Outcomes (KDIGO) 
criteria, along with the definition and staging of AKI. AKI was 
defined as any of the following: increase in serum creatinine 
by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours; increase in 
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serum creatinine to ≥1.5 times baseline, which is known or 
presumed to have occurred within the prior 7 days; or urine 
volume <0.5 mL/kg/h for 6 hours. The recommendations of 
the KDIGO of the United States National Kidney Foundation 
were taken under consideration.20,21
TAVI and main access site. Indication for TAVI was 
discussed within an interdisciplinary heart team. Access site 
was femoral in 474 patients (90.0%), transapical in 32 pa-
tients (6.0%), subclavian in 15 patients (2.9%), and direct 
aortic in 5 patients (1.0%). The valve was selected by the 
operators; the most commonly implanted valves were the 
CoreValve (Medtronic) in 237 patients (45.0%) and Edwards 
valves (Edwards Lifesciences) in 216 patients (41.0%). 
Statistical analysis. Continuous variables are expressed 
as median with interquartile range (IQR) and were com-
pared between patients with and without AKI by means of 
Mann-Whitney U-tests (all non-normally distributed by 
looking at the data and verifying with Shapiro-Wilk’s test). 
Categorical data are expressed as percentiles within the AKI 
and non-AKI groups, and were compared using the Fisher’s 
exact test. For our analysis, we further divided patients into 
diabetics and non-diabetics. Variables with a probability val-
ue of P<.05 in the univariable analysis, as well as other fac-
tors with clinical reasoning, were included in a multivariate 
logistic regression model, with AKI as the dependent vari-
able. The final model was assessed for calibration by means of 
the Hosmer-Lemeshow goodness-of-fit test.
All probability values and confidence intervals were 
two-sided. The level of statistical significance was set at a 
probability value of P<.05. Statistical analysis was performed 
using SPSS Statistics software, version 24.0 (IBM).
Results
Analysis of the whole population. Baseline charac-
teristics included a high prevalence of arterial hypertension 
in 395 patients (75.0%) and diabetes mellitus (DM) in 155 
patients (29.5%), with 334 patients (63.5%) classified as ei-
ther New York Heart Association III or IV. Median overall 
STS score was 4.87% (range, 0.7%-37.6%; mean, 6.60%). A 
complete list of baseline characteristics is shown in Table 1. 
A total of 50 patients (9.5%) developed postprocedural 
AKI within the first 7 days (Figure 1). Patients who devel-
oped AKI were more likely to have DM (44.9% vs 27.9%; 
P=.02), CKD grade ≥IV (26% vs 13.9%; P=.04), and higher 
baseline creatinine (1.30 mg/dL [IQR, 0.98-1.75 mg/dL] 
vs 1.09 mg/dL [IQR, 0.88-1.36 mg/dL]; P=.01). On the 
other hand, there were no significant differences in echo-
cardiographic findings between the groups at baseline. The 
complete list of baseline characteristics and risk factors after 
TAVI can be found in Table 2. 
Of the multiple risk scores assessed at baseline, only 
STS was significantly higher in those who developed AKI 
(6.45% [IQR, 3.48%-10.01%] vs 4.84% [IQR, 3.07%-
7.60%]; P=.03) (Table 2). 
For the assessment of possible predictive factors in the 
development of AKI, we applied a univariate logistic regres-
sion model (Figure 3). On a multivariate logistic regression 
model (corrected for baseline creatinine, DM, STS score, and 
coronary revascularization), baseline creatinine (OR, 1.605; 
95% CI, 1.111-2.319; P=.01) and DM (OR, 1.902; 95% CI, 
1.018-3.553; P=.04) were the only significant predictors 
of postprocedural AKI. The model was well calibrated by 
means of Hosmer-Lemeshow test (Chi²=4.389; P=.82).
Subanalysis of AKI in DM patients. We compared base-
line characteristics and risk factors of the diabetes subgroup 
with regard to AKI after TAVI (Table 3). Diabetic patients com-
prised 155 patients (29.5% of the study population), of which 22 
(14.2%) developed AKI. Baseline ACEF score was significantly 
higher among diabetic AKI patients (4.36 [IQR, 3.57-5.81] 
vs 3.32 [IQR, 1.46-4.79]; P<.01) (Supplementary Figure S1) 
translating into a lower baseline GFR (35.50 mL/min/1.73 m2 
[IQR, 27.62-45.13 mL/min/1.73 m2] vs 45.41 mL/min/1.73 
m2 [IQR 34.19-66.18 mL/min/1.73 m2]; P<.01) as well as a 
higher incidence of CKD grade ≥IV (40.9% vs 12.9%; P<.01). 
The overall amount of contrast used in diabetics who devel-
oped AKI was lower (84.00 mL [IQR, 55.00-295.75 mL] vs 
140.00 mL [IQR, 72.60-270.00 mL]); however, a higher ratio 
of contrast to GFR was documented in this group (mean, 5.72 
vs 4.32; median, 2.96 [IQR, 1.48-5.86] vs 2.14 [IQR, 1.20-
6.56]) (Supplementary Figure S2). Baseline echocardiographic 
assessment was not different among the groups. 
In the diabetic subgroup, a univariate logistic regression 
model for the assessment of possible predictive factors in the 
development of AKI is shown in Figure 4. For the multi-
variate logistics regression model, we corrected for contrast 
agent (mL)/GFR (OR, 0.982; 95% CI, 0.893-1.080; P=.71) 
and baseline creatinine (OR, 2.061; 95% CI, 1.154-3.683; 
P=.02). This model was also considered well calibrated by 
means of Hosmer-Lemeshow test (Chi²=4.607; P=.80). In 
the diabetic population, an elevation by 1 mg/dL in baseline 
creatinine was associated with a twofold increased risk of 
developing AKI (OR, 2.061; 95% CI, 1.154-3.683).
The univariate and multivariate analyses within the non-
DM group did not yield any significant predictors of AKI. 
No kidney function assessment had any significance in fore-
seeing AKI. However, lower hemoglobin levels had a sig-
nificant correlation in its development after TAVI (112.00 
g/L [IQR, 96.50-136.00 g/L]) vs 125.00 g/L [IQR, 114.50-
136.00 g/L]; P=.04).
Discussion 
AKI is one of the most commonly occurring adverse 
events in TAVI and is associated with lower survival5,22,23 post 
TAVI. In our analysis, which comprised mainly intermediate 
surgical risk patients with a median STS of 4.87% (mean, 
6.60%; 95% CI, 6.12-7.08), we found that AKI occurred in 
9.5% of patients, of which 78.8% had stage 1 AKI, 18.2% 
had stage 2 AKI, and 3.0% had stage 3 AKI. DM plays an 
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important role in predicting AKI 
post TAVI (OR, 1.9; 95% CI, 
1.018-3.553; P=.04) along with 
CKD stage IV and V, creatinine 
at baseline, and STS risk score 
for mortality. This result is in line 
with previous reports11,24,25 that 
showed an OR of 6.722 (P<.01) 
or a HR of 1.6 (95% CI, 1.1-
2.4) in DM patients.11,25 Diabet-
ics are at a higher risk for any 
operation or invasive treatment 
and consequently have a lower 
survival advantage.26,27 Patients 
who developed AKI (9.5%) had 
significantly higher baseline cre-
atinine (1.30 mg/dL vs 1.09 mg/
dL; P=.01) and other risk factors, 
while other commonly known 
risk factors like arterial hyper-
tension (P=.49) and peripheral 
artery disease (P=.17) did not 
statistically differ between the 
groups. In other published stud-
ies, hypertension, chronic ob-
structive pulmonary disease, and 
blood transfusion were found to 
also be predictive factors.23 This 
difference could be explained 
by our intermediate-risk popu-
lation; in addition, most of the 
factors we assessed are prepro-
cedural baseline characteristics. 
None of the echocardiographic 
findings were predictors of AKI. 
To further substantiate our 
findings, we studied the influ-
ence of contrast volume, which is 
correlated with the development 
of contrast-induced nephropathy 
after TAVI.28,29 When comparing 
the mean total amount of 110.0 
mL contrast used in patients who 
developed AKI from our cohort 
to other studies as listed in the 
meta-analysis by Wang et al,30 the 
volume was on the lower end but 
could be further reduced in the 
future. There, the median vol-
ume of contrast agent applied 
to the whole study population 
ranged from 79 ± 55 mL to 242 
± 101 mL. Patients who devel-
oped AKI post TAVI received 
Table 1. Baseline characteristics of the entire study population.
 n = 526
Diabetes mellitus 155 (29.5%)
Peripheral artery disease 90 (17.1%)
Body mass index (kg/m2) range, 15.4-44.4; mean, 26.6
Dyslipidemia 242 (46.0%)
Arterial hypertension 395 (75.1)
Coronary artery disease 273 (51.9%)
History of cerebrovascular accident 53 (10.1%)
History of myocardial infarction 71 (13.5%)
Previous pacemaker implantation 53 (10.1%)
History of PCI 135 (25.7%)
Chronic obstructive pulmonary disease 86 (16.4%)
New York Heart Association class III or IV 334 (63.5%)
Coronary artery bypass grafting 82 (15.6%)
Previous aortic valvuloplasty 8 (1.5%)
Chronic kidney disease grade IV or V 79 (15.0%)
Male sex 272 (51.7%)
Concomitant procedure 61 (11.6%)
Coronary revascularization 29 (5.5%)
Other concomitant procedure 35 (6.7%)
Severe pulmonary artery hypertension 60 (11.4%)
Aspirin 365 (69.4%)
Clopidogrel 201 (38.2%)
Vitamin K antagonist 130 (24.7%)
Novel anticoagulants 21 (4.0%)
VKA or novel anticoagulants 151 (28.7%)
Brain natriuretic peptide (pg/mL) [n = 473] median, 1266; range, 11.0-34070; mean, 2723
Baseline ACEF score [n = 519] median, 3.36; range, 0.66-8.99; mean, 3.47
Age (years) range, 36.9-96.6; mean, 81.9
GFR (mL/min/1.73 m2) [n = 524] range, 9.4-354.8; mean, 50.9
Creatinine baseline (mg/dL) [n = 525] range, 0.16-6.20; mean, 1.24
EuroScore II (%) [n = 477] median, 3.67; range, 0.60-42.58; mean, 5.3
STS score (%) [n = 525] median, 4.87; range, 0.70-37.60; mean, 6.6
Hemoglobin (g/L) [n = 335] range, 66-159; mean, 120
Total constrast during TAVI (mL) [n = 519] range, 4.00-960; mean, 189
Contrast/GFR ratio [n = 517] range, 0.15-35.98; mean, 4.46
Echocardiographic characteristics
   Aortic valve area (cm2) [n = 484] range, 0.25-1.60; mean, 0.73
   Mitral regurgitation ≥ grade 2 90 (17.1%)
   Tricuspid regurgitation ≥ grade 2 48 (9.1%)
   Ejection fraction (%) [n = 521] range, 17.0-88.0; mean, 53.7
   Mean gradient (mm Hg) [n = 515] range, 5.0-98.0; mean, 44.6
Data available for entire study population [n = 526], unless otherwise noted within brackets.  
ACEF = age, creatinine, ejection fraction; GFR = glomerular filtration rate by Cockcroft-Gault equation; 
VKA = vitamin K antagonist.
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Table 2. Baseline and echocardiographic characteristics for entire population stratified by presence of AKI post TAVI.
Characteristics Total
Patients (n)
No AKI 
(n = 476; 90.5%)
AKI 
(n = 50; 9.5%)
P-Value
Diabetes mellitus 155 133 (27.9%) 22 (44.9%) .02
Peripheral artery disease 90 78 (16.4%) 12 (24.0%) .17
Body mass index (kg/m2) 526 26.05 (23.43-29.30) 27.20 (24.33-30.68) .11
Dyslipidemia 242 219 (46.0%) 23 (46.0%) >.99
Arterial hypertension 395 355 (74.6%) 40 (80%) .49
Coronary artery disease 273 247 (51.9%) 26 (52.0%) >.99
History of cerebrovascular accident 53 45 (9.5%) 8 (16%) .14
History of myocardial infarction 71 67 (14.1%) 4 (8.0%) .28
Previous pacemaker implantation 53 46 (9.7%) 7 (14%) .32
History of percutaneous coronary intervention 135 123 (25.8%) 12 (24.0%) .87
Chronic obstructive pulmonary disease 86 78 (16.4%) 8 (16%) >.99
New York Heart Association III or IV 334 299 (62.8%) 35 (70%) .36
Coronary artery bypass graft 82 75 (21.3%) 7 (20.6%) >.99
Previous aortic valvuloplasty 8 8 (1.7%) 0 (0.0%) >.99
Chronic kidney disease grade IV or V 79 66 (13.9%) 13 (26%) .04
Male sex 272 242 (50.8%) 30 (60%) .24
Concomitant procedure 61 54 (11.3%) 7 (14.3%) .49
Coronary revascularization 29 24 (5.0%) 5 (10.2%) .18
Other concomitant procedure 35 32 (6.7%) 3 (6.1%) >.99
Severe pulmonary artery hypertension 60 54 (12%) 6 (13.6%) .81
Aspirin 365 333 (70.9%) 32 (66.7%) .62
Clopidogrel 201 186 (39.6%) 15 (31.3%) .28
Vitamin K antagonist 130 119 (25.3%) 11 (22.9%) .86
Novel anticoagulants 21 20 (5.4%) 1 (2.8%) >.99
Vitamin K antagonist or novel anticoagulants 151 139 (29.6%) 12 (25.0%) .62
Brain natriuretic peptide (pg/mL) 473 1166 (361-3028.) 1692 (698-3275) .22
Baseline ACEF score (%) 519 3.36 (2.07-4.62) 3.86 (1.91-4.94) .32
Age (years) 526 82.90 (78.93-86.73) 82.38 (79.30-85.15) .63
Weight (kg) 525 71.00 (62.00-81.00) 76.50 (65.75-84.25) .06
GFR (mL/min/1.73 m2) 524 47.86 (35.82-63.72) 41.23 (28.76-63.65) .20
Creatinine baseline (mg/dL) 525 1.09 (0.88-1.36) 1.30 (0.98-1.75) .01
EuroScore II (%) 477 3.58 (2.00-6.33) 4.76 (2.53-7.46) .10
STS score (%) 525 4.84 (3.07-7.60) 6.45 (3.48-10.01) .03
Hemoglobin (g/L) 335 122.00 (111.00-133.50) 111.50 (98.50-133.75) .04
Total constrast volume during TAVI (mL) 519 138.50 (78.75-280.00) 110.00 (60.00-300.00) .52
Contrast/GFR ratio 517 2.97 (1.55-5.89) 2.40 (1.38-7.33) .69
Echocardiographic characteristics
   Aortic valve area (cm2) 484 0.70 (0.60-0.90) 0.75 (0.60-0.90) .50
   Mitral regurgitation ≥ grade II 90 77 (16.6%) 13 (27.1%) .08
   Tricuspid regurgitation ≥ grade II 48 45 (10%) 3 (6.4%) .46
   Ejection fraction (%) 521 58.00 (45.00-61.75) 56.00 (45.00-62.00) .86
   Mean gradient (mm Hg) 515 43.00 (34.00-55.00) 40.00 (33.00-52.50) .30
Data provided as number (%) or median (range). AKI = acute kidney injury; GFR = glomerular filtration rate by Cockcroft-Gault equation.
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Table 3. Baseline and echocardiographic characteristics for diabetic subgroup stratified by presence of AKI post TAVI.
Characteristics Total
Patients (n)
No AKI 
(n = 133; 85.8%)
AKI 
(n = 22; 14.2%)
P-Value
Dyslipidemia 87 74 (55.6%) 13 (59.1%) .82
Arterial hypertension 125 105 (78.9%) 20 (90.9%) .25
Coronary artery disease 90 79 (59.4%) 11 (50.0%) .49
History of cerebrovascular event 17 14 (10.5%) 3 (13.6%) .71
Peripheral artery disease 35 30 (22.6%) 5 (22.7%) >.99
History of myocardial infarction 34 32 (24.1%) 2 (9.1%) .16
Previous pacemaker implantation 18 14 (10.6%) 4 (18.2%) .29
History of percutaneous coronary intervention 52 46 (34.6%) 6 (27.3%) .63
Chronic obstructive pulmonary disease 26 23 (17.3%) 3 (13.6%) >.99
Dyspnea New York Heart Association III or IV 109 93 (69.9%) 16 (72.7%) >.99
Coronary artery bypass graft 31 27 (24.8%) 4 (30.8%) .74
Previous aortic valvuloplasty 2 2 (1.5%) 0 (0.0%) >.99
Chronic kidney disease grade IV or V 26 17 (12.9%) 9 (40.9%) <.01
Male sex 91 79 (59.4%) 12 (54.5%) .82
Female sex 64 54 (40.6%) 10 (45.5%) .82
Concomitant procedure 16 13 (9.8%) 3 (13.6%) .70
Coronary revascularization 8 6 (4.5%) 2 (9.1%) .32
Other concomitant procedure 8 7 (5.3%) 1 (4.5%) >.99
Severe pulmonary arterial hypertension 16 12 (9.4%) 4 (23.5%) .10
Aspirin 117 101 (77.1%) 16 (72.7%) .79
Clopidogrel 60 55 (42.0%) 5 (22.7%) .10
Vitamin K antagonist 34 28 (21.4%) 6 (27.3%) .58
Novel anticoagulants 7 6 (5.6%) 1 (7.7%) .56
Vitamin K antagonist or novel anticoagulants 41 34 (26.2%) 7 (31.8%) .61
Body mass index (kg/m2) 155 27.70 (24.95-30.90) 28.95 (25.30-32.05) .44
Brain natriuretic peptide (pg/mL) 136 1243. (367-2798) 2005.50 (745-60.26.2) .17
Baseline ACEF score (%) 153 3.32 (1.46-4.79) 4.36 (3.57-5.81) <.01
Age (years) 155 80.94 (76.99-84.84) 83.65 (77.33-86.77) .26
GFR (mL/min/1.73 m2) 154 45.41 (34.19-66.18) 35.50 (27.62-45.13) <.01
Creatinine baseline (mg/dL) 154 1.18 (0.97-1.53) 1.64 (1.13-2.08) <.01
EuroScore II (%) 137 4.24 (2.44-8.42) 5.47 (4.07-10.03) .12
Society of Thoracic Surgeons score (%) 155 5.31 (3.78-8.49) 7.70 (4.79-9.83) .10
Hemoglobin (g/L) 101 116.50 (99.25-130.75) 111.00 (100.00-129.50) .96
Total constrast volume during TAVI (mL) 153 186 (72.60-270.00) 151 (55.00-295.75) .08
Weight (kg) 155 73.00 (65.50-85.00) 77.50 (69.00-85.25) .41
Contrast/GFR ratio 152 2.96 (1.48-5.86) 2.14 (1.20-6.56) .44
Echocardiographic characteristics
   Mitral regurgitation ≥ grade II 29 22 (17.1%) 7 (33.3%) .13
   Tricuspid regurgitation ≥ grade II 17 17 (13.2%) 0 (0.0%) .13
   Mean gradient (mm Hg) 154 40.50 (34.00-53.75) 37.50 (30.75-49.25) .15
   Aortic valve area (cm2) 145 0.75 (0.60-0.90) 0.80 (0.70-1.00) .05
   Ejection fraction (%) 154 57.00 (40.00-60.00) 54.00 (42.50-65.00) .76
Data provided as number (%) or median (range). 
ACEF = age, creatinine, ejection fraction; AKI = acute kidney injury; GFR = glomerular filtration rate by Cockcroft-Gault equation.
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a mean contrast volume of 187.3 mL in Yamamoto et al28 
and 261.66 mL in Marbach et al.31 Madershahian et al32 dis-
cuss the elevated risk of AKI after TAVI in patients with a 
contrast-agent burden >100 mL, which correlated with the 
findings of previous studies about percutaneous coronary 
intervention (PCI).33,34 However, no unnecessary volume of 
contrast agent was applied to our cohort. According to our 
data, operators should pay special attention to the amount of 
contrast used in DM patients. Whether the RenalGuard Sys-
tem (RenalGuard Solutions) reduces the risk of AKI in this 
particular patient population requires more data.35,36 
Although the overall contrast volume used in DM pa-
tients who developed AKI was lower than in non-DM pa-
tients, a higher ratio of contrast to GFR was documented in 
DM vs non-DM patients (mean, 5.72 vs 4.32, respectively). 
From our findings, we are proposing that future prospective 
studies should evaluate a threshold contrast volume to GFR 
ratio for DM and non-DM patients. At this point, some pub-
lications have established a maximum ratio to predict AKI 
development post TAVI, which could serve as a guide. Gi-
annini et al37 suggest that a ratio of >3.2 is correlated with a 
higher incidence of AKI and mortality after TAVI, whereas 
Gul et al38 published a ratio of >3.9 to predict postprocedur-
al contrast induced nephropathy (CIN). For DM patients, 
Wang et al39 propose a ratio of >3.1 as a possible valuable 
predictor of CIN after elective PCI, which might also be an 
indication for TAVI. 
Assessing the ideal combination of ionic/non-ionic and 
osmolality contrast agents or using dilute contrast agent could 
lead to fewer incidents of AKI. In the high-risk DM group, 
the outcome of kidney function could be improved by stag-
ing the contrast exposure. For instance, aortography could be 
performed at earlier dates and co-registered onto operative 
monitors at the time of TAVI. We further suggest assessment 
and optimization of nephrotoxic medication prior to TAVI. 
However, Rosenstock et al40 found that the incidence of CIN 
FIGURE 1. Acute kidney injury (AKI) stages: fifty patients (9.5%) 
of the entire population developed AKI; 78.8% of these pa-
tients were stage 3 AKI. crea = creatinine.
FIGURE 2. Comparison of baseline risk scores in the whole population.
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in stable patients with CKD stages III or IV does not seem 
to be influenced by withholding angiotensin-converting en-
zyme inhibitors or angiotensin receptor blockers 24 hours 
before coronary angiography. However, postprocedural hy-
dration should be optimized, and fluid resuscitation guided 
by left ventricular end-diastolic pressure could be reasonable 
to lower the risks for both prerenal and intrarenal causes of 
acute renal failure.41
For patients with severe renal impairment, contrast avoid-
ance strategies should be evaluated.  Alternative non-contrast 
based imaging modalities for aortic annulus area measure-
ment, such as transesophageal echocardiogram,42 three-di-
mensional transesophageal echocardiogram,43 or cardiovas-
cular magnetic resonance,44 could be offered. 
Study limitations. Our study has the inherent limita-
tions of any retrospective study. Even though it includes data 
from two Swiss centers, a country-wide analysis would be 
more significant. Some risk factors, such as valve calcifica-
tion and renal arteriosclerosis, were not assessed.
Conclusion 
DM is a significant predictor for AKI after TAVI. In this 
high-risk subgroup, baseline creatinine in combination with 
amount of contrast agent used over GFR influence postpro-
cedural acute renal failure. Overall poor renal function and 
a high STS score predict renal failure after TAVI. Special 
attention should be given to the amount of contrast agent 
used during interventions. 
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SUPPLEMENTARY FIGURE S1. Comparison of baseline risk scores in the diabetics supgroup.
SUPPLEMENTARY FIGURE S2. Renal parameters and ratio of contrast to glomerular filtration rate.
Co
py
rig
ht 
20
19
 
HM
P 
Co
mm
un
ica
tio
ns
 
Fo
r P
ers
on
al 
Us
e O
nly
